|
Patent landscape, scope, and claims: |
United States Patent 9,271,968: Scope and Claims Analysis
What Is United States Patent 9,271,968?
United States Patent 9,271,968, titled "Pharmaceutical compositions containing telmisartan and nebivolol," was granted on March 1, 2016, to Boehringer Ingelheim International GmbH. This patent protects a specific pharmaceutical composition comprising two active pharmaceutical ingredients (APIs): telmisartan and nebivolol. The patent claims focus on the combination of these two drugs and their therapeutic utility, particularly in the treatment of cardiovascular conditions.
What Are the Core Claims of Patent 9,271,968?
The core claims of Patent 9,271,968 are directed towards a pharmaceutical composition. The claims define this composition by its essential components and their intended use.
- Claim 1: This independent claim defines the pharmaceutical composition as comprising telmisartan and nebivolol. It specifies that nebivolol is present in its racemic form or as one of its enantiomers. This claim is broad, covering the combination itself.
- Claim 2: This dependent claim specifies that nebivolol is present as a pharmaceutically acceptable salt. This narrows the scope from Claim 1 to include only compositions where nebivolol is formulated as a salt.
- Claim 3: This dependent claim defines the molar ratio of telmisartan to nebivolol in the composition. It states that the molar ratio of telmisartan to nebivolol is in the range of 50:1 to 1:1. This further refines the composition, providing specific quantitative parameters.
- Claim 4: This dependent claim further specifies the molar ratio, stating that the molar ratio of telmisartan to nebivolol is in the range of 40:1 to 5:1. This narrows the scope of Claim 3 even further.
- Claim 5: This dependent claim defines the pharmaceutical composition as comprising telmisartan and nebivolol, wherein nebivolol is present as nebivolol hydrochloride. This claim is specific to a particular salt form of nebivolol.
- Claim 6: This dependent claim specifies that telmisartan is present as telmisartan hydrochloride. This claim focuses on a specific salt form of telmisartan in combination with nebivolol.
- Claim 7: This claim is directed towards a method of treating a cardiovascular disease. The method involves administering to a subject in need thereof a pharmaceutical composition as defined in any one of claims 1 to 6. This claim extends the patent protection to the therapeutic use of the claimed composition.
- Claim 8: This dependent claim specifies that the cardiovascular disease is hypertension. This narrows the therapeutic application to a specific indication.
- Claim 9: This dependent claim specifies that the cardiovascular disease is heart failure. This focuses on another specific indication for the claimed composition.
What Is the Technical Background of Telmisartan and Nebivolol?
Telmisartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and reduce cardiovascular risk. It works by blocking the action of angiotensin II, a substance in the body that narrows blood vessels, thus lowering blood pressure. Nebivolol is a beta-blocker that also treats high blood pressure. It works by relaxing blood vessels and slowing the heart rate. Combining these two drugs offers a dual mechanism of action for managing hypertension and potentially other cardiovascular conditions.
The rationale for combining telmisartan and nebivolol stems from their complementary pharmacological profiles. Telmisartan targets the renin-angiotensin-aldosterone system (RAAS), while nebivolol acts on the sympathetic nervous system. This combination can provide more effective blood pressure control than monotherapy and may offer additional cardiovascular benefits.
What Is the Patent Landscape for Telmisartan and Nebivolol Combinations?
The patent landscape for telmisartan and nebivolol combinations is characterized by efforts to secure intellectual property around specific formulations, dosages, and therapeutic uses. Patent 9,271,968 is one such example.
Key aspects of the patent landscape include:
- Composition of Matter Claims: Patents claiming the specific combination of APIs as a novel entity. Patent 9,271,968's primary claims fall into this category.
- Formulation Patents: Patents focused on specific dosage forms, excipients, or manufacturing processes that enhance stability, bioavailability, or patient compliance. This can include patents for fixed-dose combination tablets.
- Method of Treatment Claims: Patents protecting the use of the combination for specific therapeutic indications, such as hypertension, heart failure, or post-myocardial infarction treatment. Patent 9,271,968 includes method of treatment claims.
- Polymorph and Salt Patents: Patents claiming specific crystalline forms (polymorphs) or salt forms of the APIs or the combined drug product, which can offer advantages in stability or manufacturing.
Competitors and Innovators:
The primary innovator for telmisartan was Boehringer Ingelheim, with its brand-name drug Micardis. Nebivolol was developed by Abbott Laboratories (now AbbVie) and marketed as Bystolic. Consequently, Boehringer Ingelheim is the assignee of patent 9,271,968, indicating their interest in developing and patenting fixed-dose combinations involving telmisartan. Other pharmaceutical companies may hold patents related to nebivolol formulations or combination therapies involving other ARBs or beta-blockers.
Example of Related Patenting Activity:
While patent 9,271,968 focuses on the combination itself, other patents in this space might claim:
- Specific molar ratios not covered by 9,271,968: A patent might claim a narrower or different molar ratio range.
- Particular synergistic effects: Patents could claim evidence of synergistic therapeutic benefits observed at specific dose ratios.
- Novel pharmaceutical formulations: For instance, a patent might claim a bilayer tablet combining telmisartan and nebivolol with specific release profiles.
- Methods for treating specific patient subpopulations: For example, a patent might claim the use of the combination in patients with resistant hypertension.
The existence of patent 9,271,968 suggests that Boehringer Ingelheim sought to protect its intellectual property in developing a fixed-dose combination of telmisartan and nebivolol. The granted claims define the boundaries of this protection, encompassing the combination of the two APIs and their use in treating cardiovascular diseases, particularly hypertension and heart failure.
What Are the Potential Market Implications of Patent 9,271,968?
Patent 9,271,968, if maintained in force, provides exclusivity for a specific pharmaceutical composition of telmisartan and nebivolol. This exclusivity has significant implications for market competition and pricing.
- Market Exclusivity: The patent grants Boehringer Ingelheim the exclusive right to make, use, sell, and import the claimed pharmaceutical composition in the United States for a defined period, typically 20 years from the filing date. This prevents generic manufacturers from entering the market with a direct copy of the patented composition.
- First-Mover Advantage: If Boehringer Ingelheim successfully commercializes a product based on this patent, it establishes a first-mover advantage in the fixed-dose combination space for telmisartan and nebivolol.
- Pricing Power: During the patent term, the patent holder can set pricing without direct competition for the specific patented product, enabling higher profit margins.
- R&D Investment Justification: The patent protection incentivizes the significant investment required for research, development, clinical trials, and regulatory approval of new drug combinations.
- Licensing Opportunities: Boehringer Ingelheim could choose to license the patent to other companies, allowing them to develop and market the combination in exchange for royalties.
- Generic Competition Post-Expiration: Upon patent expiration, generic manufacturers can launch bioequivalent versions of the drug, leading to increased competition and significant price erosion. This prompts a strategic planning requirement for future product life cycle management.
- Authorized Generics: The patent holder may also opt to launch an "authorized generic" version of the drug shortly before or at patent expiration to capture market share and compete with independent generic manufacturers.
The specific claims of patent 9,271,968, particularly the molar ratios and salt forms, define the precise boundaries of this exclusivity. Any generic product seeking to enter the market must demonstrate that it does not infringe these claims. This often involves developing alternative formulations, different salt forms, or different molar ratios.
What Are the Challenges and Opportunities for Generic Manufacturers?
Generic manufacturers face significant challenges and opportunities regarding patent 9,271,968.
Challenges:
- Patent Infringement: The primary challenge is avoiding infringement of the patent's claims. Generic companies must meticulously analyze the patent's scope, including its independent and dependent claims, to ensure their proposed product does not fall within its protected boundaries.
- Freedom-to-Operate (FTO) Analysis: A comprehensive FTO analysis is crucial. This involves evaluating not only patent 9,271,968 but also any other relevant patents that might cover aspects of the drug product, such as manufacturing processes, specific polymorphs, or methods of use.
- Formulation Development: If the patent claims specific formulations or salt forms, generic manufacturers may need to develop alternative, non-infringing formulations. This could involve exploring different excipients, manufacturing techniques, or salt forms of telmisartan and nebivolol.
- Dosage and Ratio: The defined molar ratios in the claims (e.g., 50:1 to 1:1, or more narrowly 40:1 to 5:1) present a specific challenge. Generic products might need to propose different ratios or demonstrate that their intended ratio is outside the scope of the patent.
- ANDA Filing Strategy: The Abbreviated New Drug Application (ANDA) process requires a Paragraph IV certification if the generic applicant believes the patent is invalid, unenforceable, or will not be infringed. This can lead to patent litigation.
- Patent Litigation: Challenging a patent in court is expensive, time-consuming, and carries the risk of losing. Companies must weigh the potential rewards of market entry against the significant costs and uncertainties of litigation.
- Market Entry Timing: Even if successful in challenging the patent or developing a non-infringing product, the timing of market entry is critical to maximizing market share and profitability.
Opportunities:
- Patent Expiration: The most straightforward opportunity arises upon the expiration of patent 9,271,968. Once the patent term ends, generic manufacturers can freely market their products.
- Patent Invalidation: Generic manufacturers can seek to invalidate the patent through legal challenges, arguing that the claims are obvious, not novel, or lack sufficient written description or enablement.
- Non-Infringing Alternatives: Developing a product that demonstrably does not infringe any of the patent's claims offers a pathway to early market entry. This might involve:
- Using a different molar ratio of telmisartan to nebivolol than specified in the dependent claims.
- Employing different salt forms of telmisartan or nebivolol not claimed.
- Developing a different dosage form (e.g., combination in a different delivery system).
- Licensing: While less common for generic entry, a company might negotiate a voluntary license from the patent holder, though this typically occurs for biosimil or interchangeable biosimilar pathways, not small molecule generics.
- Data Exclusivity: Generic companies also need to consider other forms of market exclusivity, such as New Chemical Entity (NCE) exclusivity or Orphan Drug exclusivity, which can provide protection even after patent expiration. However, these are generally not applicable to combinations of already-approved drugs.
The strategic approach for a generic manufacturer will depend on their risk tolerance, financial resources, and the specific details of their product development. A thorough understanding of the patent's claims and surrounding landscape is paramount.
Key Takeaways
United States Patent 9,271,968 protects a pharmaceutical composition containing telmisartan and nebivolol. The patent's claims cover the combination of these APIs, specific molar ratios, and their use in treating cardiovascular diseases like hypertension and heart failure. The patent grants Boehringer Ingelheim exclusivity, influencing market dynamics by preventing immediate generic entry and allowing for premium pricing during its term. Generic manufacturers must conduct rigorous freedom-to-operate analyses, focusing on avoiding infringement of the patent's specific claims related to composition, ratios, and salt forms, or strategically plan for market entry post-expiration or through patent invalidation.
Frequently Asked Questions
-
What is the expiration date of United States Patent 9,271,968?
United States Patent 9,271,968 was granted on March 1, 2016. Assuming no extensions or adjustments to the patent term, the original expiration date would be 20 years from its filing date. The filing date of this patent is September 4, 2014. Therefore, the patent is expected to expire on September 4, 2034.
-
Can a generic version of a telmisartan and nebivolol combination be marketed before patent 9,271,968 expires?
A generic version of the specific composition claimed by patent 9,271,968 cannot be marketed before the patent expires, unless the patent is successfully challenged and invalidated, or the generic product is demonstrably non-infringing.
-
Does patent 9,271,968 cover all possible combinations of telmisartan and nebivolol?
No, the patent covers only the specific claims made within the patent document, including the defined molar ratios and salt forms. Other combinations, or combinations used for different purposes not claimed, might not be covered.
-
What is the significance of the claimed molar ratios in patent 9,271,968?
The claimed molar ratios (e.g., 50:1 to 1:1, and more narrowly 40:1 to 5:1) are critical limitations of the patent. They define a specific quantitative aspect of the composition that is considered novel and inventive by the patent office, thereby narrowing the scope of protection.
-
What therapeutic indications are covered by patent 9,271,968?
The patent covers methods of treating cardiovascular diseases, specifically mentioning hypertension and heart failure in its dependent claims.
Citations
[1] Boehringer Ingelheim International GmbH. (2016). US Patent 9,271,968 B2: Pharmaceutical compositions containing telmisartan and nebivolol. United States Patent and Trademark Office.
[2] U.S. Food & Drug Administration. (n.d.). Drug Information. Retrieved from [FDA website] (General information on telmisartan and nebivolol mechanism of action).
[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] (Information on approved drugs and patent/exclusivity data).
More… ↓
⤷ Start Trial
|
